Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged >/= 65 years in the United States. Kirk B, Bush C, Toyip A, Mues KE, et al. Vaccine 2024;42:126113.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kirk B, Bush C, Toyip A, Mues KE, et al. Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged >/= 65 years in the United States. Vaccine 2024;42:126113.
PMID: 39030080